Posted by Michael Wonder on 31 Aug 2022
Scilex announces that the FDA has granted fast track designation for SP-103 (lignocaine 5.4% topical system), next generation triple strength formulation of ZTlido for the treatment of acute low back pain
30 August 2022 - According to the CDC in 2020, low back pain was the most common type of pain reported by patients, with 25% of US adults reporting low back pain in the prior 3 months.
Scilex today announced that FDA has granted fast track designation for its investigational drug and device product candidate, SP-103.
